The vast majority of patients with pancreatic ductal adenocarcinoma (PDA) are not candidates for curative resection. Overall survival rates in this group of patients remain exceptionally low. Pancreatic cancer organoids are tumor models of individualized human PDA that can be rapidly generated from surgically resected tumors. Organoids simulate the full spectrum of a patient’s tumor, including stromal elements believed to be responsible for chemotherapy resistance. Hence, they can be used for testing personalized treatment strategies. For surgically unresectable patients, creation of human PDA organoids at the time of tissue diagnosis could allow this group of patients to benefit from precision medicine with personalized treatment.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Gastrointestinal Endoscopy
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
© 2017 Published by Elsevier Inc.